Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The house dust mite (HDM) allergen-specific immune response is a complex immunological process triggered by exposure to proteins from house dust mites. It involves both innate and adaptive immunity, with a strong bias toward Th2-type responses that promote IgE production and eosinophilic inflammation. This response is a major driver of allergic diseases such as asthma, allergic rhinitis, and atopic dermatitis. Key features include epithelial barrier disruption, activation of innate immune cells via pattern recognition receptors, Th2 polarization, allergen-specific IgE production, and mast cell/basophil degranulation upon re-exposure.
Varied; antihistamines block histamine receptors; corticosteroids suppress inflammation; immunotherapy aims to induce tolerance; bronchodilators relax airway muscles; leukotriene inhibitors block leukotriene receptors.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on House Dust Mite Allergen-Specific Immune Response (HDM Immune Response).